目的 探討西黃丸聯(lián)合紫杉醇和鉑類新輔助化療對(duì)晚期宮頸癌患者術(shù)后療效的影響。方法 選取2014年1月-2017年1月安陽市第三人民醫(yī)院收治的晚期宮頸癌患者80例為研究對(duì)象，采用隨機(jī)數(shù)字表法分為觀察組和對(duì)照組各40例，均擇期行根治性子宮切除術(shù)，術(shù)后對(duì)照組予以紫杉醇+順鉑新輔助化療方案，3周為1個(gè)療程，治療2個(gè)療程；觀察組在對(duì)照組基礎(chǔ)上予以西黃丸2次/d，治療6周。比較兩組化療有效率、生存率及復(fù)發(fā)率，測定兩組化療前后T淋巴細(xì)胞亞群（CD3⁺、CD4⁺、CD8⁺）及免疫球蛋白（IgA、IgG、IgM）水平，應(yīng)用卡氏評(píng)分表（KPS）、數(shù)字評(píng)分法（NRS）評(píng)價(jià)生活質(zhì)量及癌痛度，記錄不良反應(yīng)。結(jié)果 觀察組化療有效率（87.50%）與對(duì)照組（77.50%）比較略高，但差異無統(tǒng)計(jì)學(xué)意義；觀察組化療后3、6個(gè)月生存率、復(fù)發(fā)率與對(duì)照組對(duì)比均無統(tǒng)計(jì)學(xué)差異；化療后觀察組CD3⁺（72.39±1.47）%、CD4⁺（37.62±1.17）%、IgA （11.11±1.34） g/L、IgG （1.23±0.45） g/L、IgM （2.60±0.46） g/L較對(duì)照組明顯增加，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組CD8⁺（20.32±1.39）%低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后觀察組KPS評(píng)分（78.49±1.45）分較對(duì)照組顯著增加，而其NRS評(píng)分（1.20±0.11）較對(duì)照組明顯降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組不良反應(yīng)發(fā)生率（7.50%）明顯低于對(duì)照組（25.00%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 西黃丸西黃丸聯(lián)合紫杉醇和鉑類新輔助化療對(duì)晚期宮頸癌患者術(shù)后療效較好，可改善其免疫功能、生活質(zhì)量、疼痛度，減少不良反應(yīng)，近期不會(huì)明顯改善生存率及復(fù)發(fā)率，遠(yuǎn)期療效需進(jìn)一步研究。

Objective To investigate the effect of Xihuang Pill on the curative effect of paclitaxel combined with platinum based neoadjuvant chemotherapy in patients with advanced cervical cancer after operation. Methods 80 cases of patients with advanced cervical cancer treated in our hospitalfrom January 2014 to January 2017 were enrolled in the study. By random number table method, the patients were divided into the observation group and the control group with 40 cases in each group, and all patients were treated with radical hysterectomy. After operation, the control group were treated with paclitaxel and platinum (cisplatin) based neoadjuvant chemotherapy, while the observation group were treated with Xihuang Pill and platinum based neoadjuvant chemotherapy. The effective rate of chemotherapy, survival rate and recurrence rate were compared between the two groups. The levels of T lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺) and immunoglobulin (IgA, IgG, IgM) in two groups were determined before and after chemotherapy. The quality of life and cancer pain degree were evaluated with the Karnofsky Performance Scale (KPS) and the numeric rating scale (NRS), and adverse reactions were recorded. Results The effective rate of chemotherapy was slightly higher in the observation group than the control group (87.50% vs 77.50%). Three months and six months after chemotherapy, the survival rate and recurrence rate showed no significant difference between the two groups. After chemotherapy, percentages of CD3⁺ and CD4⁺, levels of IgA, IgG and IgM were significantly higher in the observation group than the control group (P<0.05), and the percentage of CD8⁺ was lower than the control group (P<0.05). After treatment, KPS score of the observation group was significantly higher than the control group, and NRS score was significantly lower than the control group (P<0.05). The incidence of adverse reactions was significantly lower in the observation group than the control group (7.50% vs 25.00%) (P<0.05). Conclusion Xihuang Pill combined with cisplatin based neoadjuvant chemotherapy is effective in the treatment of advanced cervical cancer after operation. The regimen can improve the immune function and quality of life, relieve pain degree and reduce adverse reactions. It will not increase the short-term survival rate and recurrence rate, and long-term efficacy needs further study.